Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma, Ewing × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 40 Small Cell Lung Carcinoma 17 Sarcoma 14 Breast Neoplasms 13 Stomach Neoplasms 8 Neoplasms 8 Lung Neoplasms 7 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 5 Ovarian Neoplasms 5 NSCLC 5 Nasopharyngeal Carcinoma 4 Esophageal Neoplasms 4 Uterine Cervical Neoplasms 3 Neoplasm Metastasis 3 Glioma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Carcinoma 3 Brain Neoplasms 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2 Pheochromocytoma 2

Interventions

Cyclophosphamide 21 Temozolomide 19 Irinotecan 16 Vincristine 14 Doxorubicin 11 Topotecan 10 Melphalan 10 Etoposide 9 Busulfan 8 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Magnetic Resonance Spectroscopy 6 Filgrastim 6 cabozantinib 5 X-Rays 5 Sirolimus 5 Drug Therapy 5 pegfilgrastim 4 palbociclib 4 liposomal doxorubicin 4 fludarabine phosphate 4 fludarabine 4 Trabectedin 4 Specimen Handling 4 Phantoms, Imaging 4 Gemcitabine 4 regorafenib 3 irinotecan sucrosofate 3 ganitumab 3 abemaciclib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡